癌症（英文版）2016，Vol.56Issue(11)：604-616,13.DOI:10.1186/s40880-016-0145-8
ORIGINAL ARTICLE
Associations of genetic polymorphisms
of the transporters organic cation transporter 2
(OCT2), multidrug and toxin extrusion 1 (MATE1),
and ATP‑binding cassette subfamily C member
2 (ABCC2) with platinum‑based chemotherapy
response and toxicity in non‑small cell lung
cancer patients
ChenYueQian 1YiZheng 2YingWang 3JuanChen 1JunYanLiu 4HongHaoZhou 1JiYeYin 1ZhaoQian Liu1
作者信息
- 1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, P. R. China
- 2. Key Laboratory of Hunan Province for Traditional Chinese Medicine in Obstetrics & Gynecology Research, The Maternal and Child Health Hospital of Hunan Province, Changsha 410008, Hunan, P. R. China
- 3. The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410008, Hunan, P. R. China
- 4. Xiangya School of Medicine, Central South University, Changsha 410008, Hunan, P. R. China
- 折叠
摘要
Abstract
Background:Platinum‑based chemotherapy is the ifrst‑line treatment of non‑small cell lung cancer (NSCLC); it is therefore important to discover biomarkers that can be used to predict the effcacy and toxicity of this treatment. Four important transporter genes are expressed in the kidney, including organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), ATP‑binding cassette subfamily B member 1 (ABCB1), and ATP‑binding cassette subfamily C member 2 (ABCC2), and genetic polymorphisms in these genes may alter the effcacy and adverse effects of platinum drugs. This study aimed to evaluate the association of genetic polymorphisms of these transporters with platinum‑based chemotherapy response and toxicity in NSCLC patients. Methods:A total of 403 Chinese NSCLC patients were recruited for this study. All patients were newly diagnosed with NSCLC and received at least two cycles of platinum‑based chemotherapy. The tumor response and toxicity were evaluated after two cycles of treatment, and the patients’ genomic DNA was extracted. Seven single‑nucleotide polymorphisms in four transporter genes were selected to investigate their associations with platinum‑based chemo‑therapy toxicity and response. Results:OCT2 rs316019 was associated with hepatotoxicity (P=0.026) and hematological toxicity (P=0.039), and MATE1 rs2289669 was associated with hematological toxicity induced by platinum (P=0.016). In addition,ABCC2 rs717620 was signiifcantly associated with the platinum‑based chemotherapy response (P=0.031).ABCB1 polymor‑phisms were associated with neither response nor toxicity. Conclusion:OCT2 rs316019,MATE1 rs2289669, andABCC2 rs717620 might be potential clinical markers for predicting chemotherapy toxicity and response induced by platinum‑based treatment in NSCLC patients. Trial registration Chinese Clinical Trial Registry ChiCTR‑RNC‑12002892关键词
OCT2/MATE1/ABCC2/Non-small cell lung cancer/Platinum-based chemotherapyKey words
OCT2/MATE1/ABCC2/Non-small cell lung cancer/Platinum-based chemotherapy引用本文复制引用
ChenYueQian,YiZheng,YingWang,JuanChen,JunYanLiu,HongHaoZhou,JiYeYin,ZhaoQian Liu..ORIGINAL ARTICLE
Associations of genetic polymorphisms
of the transporters organic cation transporter 2
(OCT2), multidrug and toxin extrusion 1 (MATE1),
and ATP‑binding cassette subfamily C member
2 (ABCC2) with platinum‑based chemotherapy
response and toxicity in non‑small cell lung
cancer patients[J].癌症（英文版）,2016,56(11):604-616,13.
